Clinical Adoption Leverage proven clinical interest and upcoming regulatory clearance to drive clinic and hospital partnerships. The platform is already used by a substantial patient base and benefits from guidance of esteemed clinicians, creating a strong value proposition for hospitals, clinics, and integrated health networks seeking scalable mental health treatments. Focus outreach on psychiatry clinics, primary care networks, sleep centers, and veteran health programs to secure partnerships around adoption, training, and ongoing support ahead of regulatory clearance for the Version 2.0 OAK device.

Financing Access Pricing remains a barrier to mass adoption, creating a clear opportunity to sell via clinics and partnerships with financing, leasing, or subscription options, and to bundle with the Kortex VR integration to boost value and adherence. Target employers, health plans, and patient assistance programs to broaden reach and build scalable revenue streams for partners.

Regulatory Readiness Regulatory readiness and trusted clinical endorsement can accelerate sales. With the OAK device designed for smartphone-scale deployment and on track for regulatory approval, engage with hospital systems, VA networks, and academic medical centers to position the product as a preferred depression and anxiety treatment option. Leverage the advisory network of leading psychiatrists and veterans health leaders to secure procurement conversations and reimbursement planning.

Partnership Potential Strategic collaborations and product ecosystem leverage. The collaboration with notable tech teams behind consumer brands signals strong consumer tech credentials and scalable distribution potential. Explore co marketing and integration partnerships with telemedicine providers, digital health platforms, and sleep mental health apps, plus cross sell opportunities with the Kortex VR platform to create a comprehensive at home therapy package for clinicians and patients.

Competitive Differentiation Position Fisher Wallace Laboratories as an FDA approved consumer device with a proven patient footprint and upcoming regulatory milestone, complemented by a VR and neurostimulation ecosystem. Target health systems, insurers, and multinational employers who value accessible, evidence based mental health tools and scalable at home treatment options. Emphasize clinical validation, advisory support, and post market education to win pilots and larger contracts.